Real-world evidence

Cancer Medicines Forum: March 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, 2 March 2026

Quarterly System Demo - Q2 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 25 June 2026, 09:00 (CEST) to 25 June 2026, 12:40 (CEST)

List of medicines currently in PRIME scheme

Human medicines European public assessment report (EPAR): Winrevair, sotatercept, Date of authorisation: 22/08/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Ultomiris, ravulizumab, Date of authorisation: 02/07/2019, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Dovprela (previously Pretomanid FGK), pretomanid, Date of authorisation: 31/07/2020, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Tepkinly, epcoritamab, Date of authorisation: 22/09/2023, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Sarclisa, isatuximab, Date of authorisation: 30/05/2020, Revision: 14, Status: Authorised